Bloomberg Report Excerpt: CytoDyn Inc. (OTCQB: C

Bloomberg Report Excerpt: CytoDyn Inc. (OTCQB: CYDY) announced last week it is offering comprehensive
cytokine profiling (including RANTES levels) through its diagnostic partner
company, IncellDx, to help physicians understand the pathogenesis of Childhood
Inflammatory Disease Related to COVID-19. These laboratory tests are
exploratory in nature and not intended for clinical decision making.

Recent reports in parts of the U.S. and Europe suggest a rare and potentially
fatal inflammatory disease linked to the novel coronavirus is afflicting a
small number of children. The condition resembles a rare childhood illness
called Kawasaki disease, which has similar signs and symptoms and can lead to
enlargement of blood vessels that in severe forms may cause heart
damage. Nader Pourhassan, Ph.D., President and Chief Executive Officer of
CytoDyn added, "We hope our comprehensive cytokine testing will help
physicians gain a better understanding of the disease process and, in turn,
explore the prospect for leronlimab to potentially provide a therapeutic
benefit to children suffering from inflammatory illness related to COVID-19."
https://www.bloomberg.com/press-releases/2020...bal-unrest